| CAP patients | Control subjects | P value |
---|---|---|---|
Size, n | 75 | 41 | Â |
Demographics | |||
Age, year, mean (SD) | 70.67 (13.31) | 69.37 (8.60) | 0.574d |
Sex, male, n (%) | 41 (54.7) | 24 (58.5) | 0.837c |
Ethnicity, Caucasian, n (%) | 53 (70.7) | 36 (87.8) | 0.063c |
Body Mass Index, median [Q1, Q3] | 25.93 [23.07, 28.41] | 26.36 [24.74, 29.58] | 0.177b |
Chronic comorbidities, n (%) | |||
COPD | 26 (34.7) | 4 (9.8) | 0.007c |
Cardiovascular disease | 58 (77.3) | 25 (61.0) | 0.099c |
Diabetes | 19 (25.3) | 4 (9.8) | 0.077c |
Malignancy | 20 (26.7) | 8 (19.5) | 0.526c |
Chronic renal disease | 7 (9.3) | 1 (2.4) | 0.309c |
Immunosuppressiona | 4 (5.3) | 2 (4.9) | 0.99c |
Disease severity, median [Q1, Q3] | |||
PSI score | 4.00 [3.00, 4.00] | – |  |
SOFA score | 0.00 [0.00, 1.00] | – |  |
Causal pathogen, n (%) |  | – |  |
Streptococcus pneumoniae | 10 (13.33) | – |  |
Haemophilus influenzae | 7 (9.33) | – |  |
Staphylococcus aureus | 4 (5.33) | – |  |
Influenza A virus | 6 (8) | – |  |
Influenza B virus | 3 (4) | – |  |
Rhinovirus | 3 (4) | – |  |
Coronavirus type NL63 | 1 (1.33) | – |  |
Respiratory syncytial virus | 2 (2.67) | – |  |
Human metapneumovirus | 2 (2.67) | – |  |
Parainfluenza virus 1–4 | 2 (2.67) | – |  |
No causative pathogen identified | 39 (52) | – |  |
Outcome | |||
ICU admission, n (%) | 5 (6.7) | – |  |
Hospital LoS, days, median [Q1, Q3] | 5.00 [3.00, 8.75] | – |  |
Hospital mortality, n (%) | 1 (1.4) | – |  |
Day 28 mortality, n (%) | 4 (6.1) | – |  |